Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream

Clinical and Experimental Dermatology

Volumn 36, Issue 5, 2011, Pages 509-511

  Arun, B ^a   Pearson, J ^a   Chalmers, R ^a  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

AGED; ARTICLE; CASE REPORT; DISSEMINATED SUPERFICIAL ACTINIC POROKERATOSIS; DISSEMINATED SUPERFICIAL POROKERATOSIS; DRUG EFFICACY; EPIDERMIS; ERYTHEMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOMELANOSIS; INFLAMMATION; MALE; PHYSICAL EXAMINATION; POROKERATOSIS; PRIORITY JOURNAL; PRURITUS; SCAR FORMATION; SKIN BIOPSY; SKIN DEFECT;

ADMINISTRATION, CUTANEOUS; AGED; AMINOQUINOLINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON INDUCERS; MALE; POROKERATOSIS;

EID: 79959333683     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04064.x     Document Type: Article

References (7)

1. Chernosky ME, Rapini RP. Squamous cell carcinoma in lesions of disseminated superficial actinic porokeratosis: a report of two cases. Arch Dermatol 1986; 122: 853-5.
2. Hemmi H, Kaisho T, Sato S et al. Small anti-viral compounds activate cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
3. Testerman TL, Gerster JF, Imbertson LM et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58: 365-72.
4. Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Australas J Dermatol 2003; 44: 281-3.
5. Ahn SJ, Lee HJ, Chang SE et al. Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007; 34: 146-7.
6. Jensen JM, Egberts F, Proksch E, Hauschild A. Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy. Acta Derm Venereol 2005; 85: 550-1.
7. Erbagci Z, Tuncel AA, Erbagci I. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases. J Drugs Dermatol 2006; 5: 668-71.